728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Perlmutter Cancer Center Names New Director of Gastrointestinal Medical Oncology

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

BROOKLYN, N.Y., Feb. 6, 2018 /PRNewswire-USNewswire/ — Paul E. Oberstein, MD, a nationally renowned clinician-scientist, will join NYU Langone Health and its Perlmutter Cancer Center on March 1 as director of Gastrointestinal (GI) Medical Oncology and assistant director of its recently established Pancreatic Cancer Center.

Dr. Paul Oberstein, named new Director of Gastrointestinal Medical Oncology at NYU Langone’s Perlmutter Cancer Center.

Prior to his new post at NYU Langone, Dr. Oberstein was a member of the Herbert Irving Comprehensive Cancer Center at Columbia University, an assistant professor at Columbia University College of Physicians & Surgeons and an attending physician at New York-Presbyterian/Columbia University Medical Center. 

Dr. Oberstein’s recruitment marks an exciting expansion in innovative and potentially practice-changing clinical trials research in GI cancers at Perlmutter Cancer Center. His research focuses on the design and implementation of translational studies that apply novel laboratory concepts to patients. His recent work includes biomarker research to understand the immune microenvironment of cancer cells, investigation of a new imaging method for detecting pancreatic tumors, and testing new combinations of chemotherapy and immunotherapy in advanced pancreas cancer patients.

Dr. Oberstein also will see patients and expedite the progression of laboratory studies and research on all types of GI cancers to clinical practice.

“In 2018, for the first time, GI cancers will cause more cancer deaths in the United States than any other organ system,” says Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center. “Dr. Oberstein’s experience in designing clinical trials for these cancers and his expertise in bringing basic research findings to the patient’s bedside strengthen our already formidable GI cancer research team.”

At Perlmutter Cancer Center, Dr. Oberstein will collaborate with many medical and surgical leaders in GI cancer. They include Diane M. Simeone, MD, the Laura and Isaac Perlmutter Professor of Surgery, professor of Pathology, and director of its Pancreatic Cancer Center; George Miller, MD, the H. Leon Pachter, MD Professor of Surgery and professor of Cell Biology; H. Leon Pachter, MD, the George David Stewart Professor of Surgery and chair of the Department of Surgery; Alec Kimmelman, MD, PhD, professor of Radiation Oncology and the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology; Deirdre J. Cohen, MD, assistant professor of Medicine; Paresh C. Shah, MD, clinical professor of Surgery,

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *